Amy Vaccine Co., Ltd. announced that it has submitted a pre-application for clinical trials of mRNA RSV vaccine and mRNA shingles vaccine to the U.S. Food and Drug Administration (FDA) in August 2024. This is in line with Amy Vaccine's international strategy and the good data demonstrated in animal studies. If approved by the FDA, it will help accelerate the clinical trials and commercialization process of the vaccine worldwide. Currently, there is no approved mRNA shingles vaccine on the market globally, and there is also no approved RSV vaccine in China. Amy Vaccine has established a comprehensive mRNA vaccine research and production system, obtained relevant technology patents, and is committed to meeting the clinical needs in core disease areas.

Amy Vaccine Co., Ltd. announced that it has submitted a pre-application for clinical trials of mRNA RSV vaccine and mRNA shingles vaccine to the U.S. Food and Drug Administration (FDA) in August 2024. This is in line with Amy Vaccine's international strategy and the good data demonstrated in animal studies. If approved by the FDA, it will help accelerate the clinical trials and commercialization process of the vaccine worldwide. Currently, there is no approved mRNA shingles vaccine on the market globally, and there is also no approved RSV vaccine in China. Amy Vaccine has established a comprehensive mRNA vaccine research and production system, obtained relevant technology patents, and is committed to meeting the clinical needs in core disease areas.